Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curaxil (Trastuzumab) for bone marrow protection during BEP chemotherapy in germ cell tumors
ChiCTR2600121923Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in Malignant ovarian germ cell tumor (OGCT) and germ cell tumor (GCT), sponsored by Shandong First Medical University. Primary endpoint: Incidence of grade ≥ 3 neutropenia in the first cycle of chemotherapy. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Malignant ovarian germ cell tumor (OGCT)germ cell tumor (GCT)
Beyond the preview
Go deeper on ChiCTR2600121923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121923.